Sia/LBG’s Andrew B. Harmon, a recognized subject matter expert providing strategic insights across the biopharmaceutical industry, recently presented a forward-looking model for the viral vector market at BioProcess International Europe in Hamburg, Germany.
In his presentation, Mr. Harmon addressed the evolving manufacturing landscape for viral vectors and capacity planning challenges facing Contract Development and Manufacturing Organizations (CDMOs).
“The industry built impressive manufacturing capability, but market realities remind us that strategic planning matters most when demand doesn’t unfold as predicted.” — Andrew Harmon
Following his well-received talk, a detailed article titled “Modeling Viral Vector Capacity: Healthy Growth by 2031” was published in BioProcess Insider on June 25, 2025. Authored by Cheryl Scott, the article highlights Mr. Harmon’s data-driven approach to market intelligence, including his analysis of current viral vector market dynamics and challenges facing the broader cell and gene therapy manufacturing sector.
“Rapid advancement of gene therapy has driven a surge in demand for clinical-grade viral vectors. Can the industry meet that demand with manufacturing capacity? The short answer is ‘Yes — and then some!’” — BioProcess Insider
Read the full article: Modeling viral vector capacity: Healthy growth by 2031